Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03035331 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
A Phase 1 study of Small Lymphocytic Lymphoma and Recurrent Diffuse Large B-Cell Lymphoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03035331 is a Phase 1 study of Small Lymphocytic Lymphoma and Recurrent Diffuse Large B-Cell Lymphoma that has completed, run by Mayo Clinic. The registered enrollment target is 11 participants, below the 193-participant average among 81 other Small Lymphocytic Lymphoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03035331, a Phase 1 study of Small Lymphocytic Lymphoma and Recurrent Diffuse Large B-Cell Lymphoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Cryosurgery
- BIOLOGICAL Pneumococcal 13-valent Conjugate Vaccine
- BIOLOGICAL Dendritic Cell Therapy
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2022-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03035331
The ClinicalTrials.gov registry entry for NCT03035331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 81 other Small Lymphocytic Lymphoma trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Small Lymphocytic Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03035331 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03035331 about?
NCT03035331 is a clinical study titled "Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma". This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective i...
What is the current status of trial NCT03035331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-08-15. Estimated completion is 2022-09-10.
What conditions does trial NCT03035331 study?
This clinical trial studies the following conditions: Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT03035331?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Cryosurgery (PROCEDURE), Pneumococcal 13-valent Conjugate Vaccine (BIOLOGICAL), Dendritic Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03035331?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03035331 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Lymphocytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
RECRUITING · Phase 1
-
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
RECRUITING · Phase 1
-
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RECRUITING · Phase 1
-
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RECRUITING · Phase 1
-
Mosunetuzumab for CLL MRD Clearance
RECRUITING · Phase 1
Explore more on PlainTrial
Small Lymphocytic Lymphoma
All registered trials for this condition
Recurrent Diffuse Large B-Cell Lymphoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.